While 2013 was a great year, 2014 promises to be even better. As we look ahead, our focus on facilitating thoughtful discussions on some of the most important health care topics will continue.
Most Recent Posts
Last week, the Administration gave a boost to NASA, vowing to keep the International Space Station in orbit until 2024, four years longer than its current approved tenure. With so many questions left unanswered and so much unchartered territory, space exploration is a lot like the search for treatments and cures.
Technology is rapidly changing how we conduct even the simplest of daily tasks, and with smartphones, tablets, and other mobile devices, being “connected” is no longer a function of sitting at a desk in front of a computer. We now carry some of the most powerful computers in the palm of our hands, and mobile platforms have opened the door to the creation of some incredibly innovative applications.
Earlier this week, Scientific American published an excellent blog post by chemist Ashutosh Jogalekar with the cheeky title, “Why drugs are expensive: It’s the science, stupid.” In his well-informed commentary, Jogalekar describe
Looking for the latest data on retail prescription drug spending? We’ve got it here. Yesterday, CMS’ Office of the Actuary released its latest figures on national health care and prescription drug spending for 2012.
This is the third blog post in a series of responses to Luke Timmerman’s Xconomy article, “12 Things the Pharma Industry Can Do to Rebuild Real Public Trust,” in which he says the pharmaceutical industry isn’t doing enough to deliver “big health advances.”
A recent article in Information Week authored by Robert Atkinson, President of the Information Technology and Innovation Foundation, makes an interesting argument about why innovation-focused industries, such as the biopharmaceutical sector, should come together on issues of innovation in order to maintain U.S. competitiveness.
This is the second blog post in a series of responses to Luke Timmerman’s Xconomy article, “12 Things the Pharma Industry Can Do to Rebuild Real Public Trust,” in which he says the pharmaceutical industry isn’t doing enough to deliver “big health advances.
This is the first blog post in a series of responses to Luke Timmerman’s Xconomy article, “12 Things the Pharma Industry Can Do to Rebuild Real Public Trust,” in which he says the pharmaceutical industry isn’t doing enough to deliver “big health advances.”
The assessment of the benefit-risk balance of a medicine is a key component of the drug development and regulatory review process. This assessment is also an important determination that each patient and doctor must make when choosing a treatment strategy.
The best health stems from the best information, and this includes biopharmaceutical information-sharing with physicians and patients. As the creators of many of the medicines we all rely upon, the companies have the most up to date knowledge on safety and benefit/risk, making conversations with prescribing physicians imperative to better care.
Rather than trying to uncover what’s at play behind a woman’s struggle to pay for the costs of her leukemia medicine, last night’s ABC World News with Diane Sawyer barely scratched the surface of a complex issue. The result: a one-sided, overly simplistic view of the cost of cancer medicines in the United States.
When we launched Conversations in June of this year, our goal was to blend formal contributors with an ongoing opportunity for experts and thought leaders to weigh in on a broad range of high-level policy topics. The forum has been a tremendous success.
Last week, I had the opportunity to participate in a panel discussion at the Elsevier Business Intelligence FDA/CMS Summit entitled, “Beyond the Label.”